Over the past decade, Aurangabad — now Chhatrapati Sambhaji Nagar — has quietly become one of India's most important pharmaceutical manufacturing zones, anchored by the MIDC Shendra industrial estate.

Why Maharashtra, and why here?

Maharashtra already hosts a dense pharmaceutical ecosystem — from bulk drug manufacturers to formulation companies and testing laboratories. Aurangabad's position within this network gives api intermediates manufacturers access to skilled technical labour, established logistics routes to Mumbai and Pune ports, and a regulatory environment increasingly familiar with WHO-GMP audit requirements.

What sets the region apart

  • Concentration of WHO-GMP certified facilities within a compact industrial radius
  • Direct road and rail connectivity to Mumbai's JNPT port for export shipments
  • A growing base of quality control laboratories supporting third-party verification
  • Lower operating costs than more saturated pharma hubs, passed through to buyers

What this means for global buyers

Sourcing from Aurangabad-based manufacturers increasingly means access to DMF-grade api intermediatess at competitive pricing, without sacrificing documentation quality. Swapnroop Drugs and Pharmaceuticals has operated from MIDC Shendra since 2013, exporting to 25+ countries with full regulatory support.